Silence Therapeutics PLC Additional Listing (5183L)
April 19 2018 - 12:00PM
UK Regulatory
TIDMSLN
RNS Number : 5183L
Silence Therapeutics PLC
19 April 2018
Additional listing
19 April 2018
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery, delivery, and development of novel RNA
therapeutics for the treatment of serious diseases with unmet
medical need, announces that it has issued and allotted 48,309 new
ordinary shares of 5p each ("Ordinary Shares") following the
exercise of share options under the Employee Share Scheme.
Application has been made to the London Stock Exchange for the
New Ordinary Shares to be admitted to trading on AIM. Admission is
expected to be effective on 25 April 2018. The Ordinary Shares
shall rank pari passu with the existing ordinary shares in the
Company.
The total number of shares in issue, following admission, will
be 70,069,933. The Company holds no shares in Treasury.
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20 3457 6900
Ali Mortazavi, Chief Executive Officer
David Ellam, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Tel: +44 (0)20 7418 8900
Broker)
James Steel/Oliver Jackson
Media Enquiries:
Optimum Strategic Communications Tel: +44 (0) 20 3714 1788
Mary Clark/ Eva Haas/Hollie Vile
silence@optimumcomms.com
IR Enquires - US Tel: +1 (212) 213 0006
Burns McClellan
John Grimaldi
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by
harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Our proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using our enabling delivery
systems, we have achieved an additional level of specificity by
delivering our therapeutic RNA molecules exclusively to target
cells. Silence's proprietary RNA chemistries and delivery systems
are designed to improve the stability of our molecules and enhance
effective delivery to target cells, providing a powerful modular
technology well suited to tackle life-threatening diseases. For
more information, please visit:
http://www.silence-therapeutics.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
ALSGGUMWCUPRGCB
(END) Dow Jones Newswires
April 19, 2018 12:00 ET (16:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024